This is a working overview of tetrapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-09 and is reviewed periodically as new material appears.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, dry powder | -20 degrees Celsius or lower | Sealed, dark, low humidity |
| Storage temperature, solution | 2 to 8 degrees Celsius | Short-term use expected |
| Primary purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Electrospray mass spectrometry | Compared with calculated mass |
| Typical purity specification | Area percent of 95 or higher | Depends on column and gradient |
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.
Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.
== Safety and regulatory actions == In March 2025, the FDA issued Dexcom a warning letter following inspections of facilities that manufactured G6 and G7 sensors. The agency said the devices were adulterated because manufacturing methods and controls did not conform to federal quality-system requirements. The letter cited inadequate process monitoring and validation, deficiencies in design controls and risk analysis—including risks associated with automated insulin delivery—and commercial distribution of sensors after major manufacturing changes without a required new premarket notification. In 2025, Dexcom recalled certain G6, G7, ONE, and ONE+ receivers because a speaker malfunction could prevent audible alerts for dangerously high or low glucose. The FDA classified the action as the most serious type of recall and reported at least 56 injuries and no deaths. Affected users were advised to check their receiver, request a replacement, and test its speaker whenever it was charged. In May 2026, Dexcom announced that G7 sensors from two lots which had been designated as scrap were stolen during disposal and sold by third parties. The company said one lot included sensors that were not properly sterilized, increasing the risk of skin infection, while the other had an elevated internal-testing failure rate and an increased risk of producing no readings. Dexcom advised users not to use sensors from the two lots and offered replacements; at the time of the announcement, no severe adverse events had been reported.
== Species distribution == Hemocyanin was first discovered in Octopus vulgaris by Leon Fredericq in 1878. The presence of copper in molluscs was detected even earlier by Bartolomeo Bizio in 1833. Hemocyanins are found in the Mollusca and Arthropoda, including cephalopods and crustaceans, and utilized by some land arthropods such as the tarantula Eurypelma californicum, the emperor scorpion, and the centipede Scutigera coleoptrata. Also, larval storage proteins in many insects appear to be derived from hemocyanins.
Mimosa tenuiflora, syn. Mimosa hostilis, also known as jurema preta, calumbi (Brazil), tepezcohuite (México), carbonal, cabrera, jurema, black jurema, and binho de jurema, is a perennial tree or shrub native to the northeastern region of Brazil (Paraíba, Rio Grande do Norte, Ceará, Pernambuco, Bahia) and found as far north as southern Mexico (Oaxaca and coast of Chiapas), and the following countries: El Salvador, Honduras, Panama, Colombia and Venezuela. It is most often found in lower altitudes, but it can be found as high as 1,000 m (3,300 ft).
Sources: en.wikipedia.org
== Causes == Gynecomastia is thought to be caused by an altered ratio of estrogens to androgens mediated by an increase in estrogen action, a decrease in androgen action, or a combination of these two factors. Estrogen and androgens have opposing actions on breast tissue: estrogens stimulate proliferation while androgens inhibit proliferation. The cause of gynecomastia is unknown in around 25% of cases. Known causes can be physiologic (occurring normally) or non-physiologic due to underlying pathologies such as drug use, chronic disease, tumors, or malnutrition.
It tends not to share the common blue tint with a vein however. It can be felt as a hardened lump or "vein" even when the penis is flaccid, and is even more prominent during an erection. It is considered a benign physical condition. It is fairly common and can follow a particularly vigorous sexual activity for men, and tends to go away if given rest and more gentle care, for example by use of lubricants. Carcinoma of the penis is rare with a reported rate of 1 person in 100,000 in developed countries. Some sources state that circumcision can protect against this disease, but this notion remains controversial among medical circles. Hard flaccid syndrome is a rare, chronic condition characterized by a flaccid penis that remains in a firm, semi-rigid state in the absence of sexual arousal. Cold glans syndrome is a condition marked by the persistent inability of the glans penis to maintain an erect state during sexual arousal, potentially leading to reduced sensitivity and erection difficulties.
19 December – UK government minister Tulip Siddiq is named in an investigation into allegations her family embezzled up to £3.9bn from infrastructure projects in Bangladesh. Jane Meagher is voted to replace Cammy Day as leader of Edinburgh City Council, and will lead a Labour minority administration. The Stormont Executive agrees to release its draft budget for the 2025/26 financial year for public consultation, with much of the £19bn budget earmarked for health and education. 20 December – Labour appoint 30 new peers, including former Downing Street chief of staff Sue Gray, while the Conservatives appoint six, including former deputy prime minister Therese Coffey. Peter Mandelson is appointed as the next UK ambassador to the United States. 21 December – US president-elect Donald Trump appoints British TV executive Mark Burnett as the inaugural United States Special Envoy to the United Kingdom. 23 December – Sir Keir Starmer holds talks with Ukrainian president Volodymyr Zelenskyy during which they agreed on the "importance of refining" the UK's training of Ukrainian forces to "bolster" Ukraine's defence. Conservative leader Kemi Badenoch says there is no "quick fix" for the Conservative Party following its election loss, and that she will not be rushed into making policy announcements. 26 December – The Reform UK website, and its leader, Nigel Farage, have said that party membership has passed the 131,680 declared by the Conservatives.
==== 20th century ==== In response to concerns about the risks of occupational polonium exposure, quantities of 210Po were administered to five human volunteers at the University of Rochester from 1944 to 1947, in order to study its biological behaviour. These studies were funded by the Manhattan Project and the AEC. Four men and a woman participated, all suffering from terminal cancers, and ranged in age from their early thirties to early forties; all were chosen because experimenters wanted subjects who had not been exposed to polonium either through work or accident. 210Po was injected into four hospitalised patients, and orally given to a fifth. None of the administered doses (all ranging from 0.17 to 0.30 μCi kg−1) approached fatal quantities. The first documented death directly resulting from polonium poisoning occurred in the Soviet Union, on 10 July 1954. An unidentified 41-year-old man presented for medical treatment on 29 June, with severe vomiting and fever; the previous day, he had been working for five hours in an area in which, unknown to him, a capsule containing 210Po had depressurised and begun to disperse in aerosol form. Over this period, his total intake of airborne 210Po was estimated at 0.11 GBq (almost 25 times the estimated LD50 by inhalation of 4.5 MBq). Despite treatment, his condition continued to worsen and he died 13 days after the exposure event. From 1955 to 1957 the Windscale Piles had been releasing polonium-210.
Sources: en.wikipedia.org
The dry powder is typically held at -20 degrees Celsius or lower, protected from light and moisture. Allowing a sealed vial to reach room temperature before opening reduces condensation on its contents. Conditions stated on a supplier certificate of analysis take precedence over general guidance.
Mass spectrometry supplies an observed molecular mass that is compared with the calculated value for the tetrapeptide. Reversed-phase chromatography then separates the main peak from related impurities. Neither technique alone establishes residue order, so sequence-level confirmation may call for tandem mass spectrometry or amino acid analysis.
No single published figure applies, because stability depends on pH, concentration, temperature and sterility. Cold storage slows hydrolysis without halting it, and microbial growth is a separate concern in non-sterile solutions. Most laboratories rely on their own analytical checks rather than a fixed expiry period.
It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.